Status:
UNKNOWN
Intense Pulsed Light Therapy in Meibomian Gland Dysfunction
Lead Sponsor:
Dar Al Shifa Hospital
Conditions:
Meibomian Gland Dysfunction
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
to evaluate the effect of intense pulsed light on resistant patients with Meibomian gland dysfunction
Eligibility Criteria
Inclusion
- age of at least 20 years.
- The diagnosis of obstructive MGD based on ocular symptoms, plugged gland orifices, vascularity and irregularity of lid margins, and reduced meibum expression (meibum grade of .1, where grade 0 = clear meibum easily expressed, grade 1 = cloudy meibum expressed with mild pressure, grade 2 = cloudy meibum expressed with more than moderate pressure, and grade 3 = meibum could not be expressed even with strong pressure).
- failure of at least 3 types of conventional MGD therapy to improve symptoms or objective findings for at least 1 year before study treatment
Exclusion
- the presence of active skin lesions, skin cancer, or other specific skin pathology.
- active ocular infection or ocular inflammatory disease.
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04904874
Start Date
December 1 2020
End Date
July 30 2021
Last Update
May 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dar alshif hospital
Kuwait City, Kuwait